Results (continued)

Chronic pain affects more than 115 million American adults. [1]

• On June 23, 2011, MediCom Worldwide, Inc. sent an email invitation to almost 30,000 Emerging Solutions in Pain
members (emailed address was verified), inviting them to participate in an 18-question online survey about issues related to safe prescribing and knowledge of the FDA Risk Evaluation and Mitigation Strategies (REMS) for all extended-release and long-acting opioid products. These clinicians were also asked to respond to questions about their current opioid prescribing as well as on various components of the REMS.

• Of the 2,870 members who received the invitation, 702 opened the email invitation, 572 clicked the link to open the survey, and 638 completed the survey.

• The survey was developed with question logic skip logic to one or more answer choices, so not all participants needed to respond to all questions.

• The average time for completion was approximately 6 minutes.

• The survey results were not maintained on an individual basis; instead all survey participants' data were collected and analyzed in aggregate.

• The 2,870 invited participants represented an estimated 2.0% of the addressable audience.

• Thirty-five percent had not yet heard of or read about the FDA REMS elements, while 72% said that there is currently not enough information available to health care professionals about REMS. [2]

• Will the opioid REMS program become an emerging solution in pain? Will it improve the undertreatment of pain and reduce the rates of misuse?

• Prescribing practices showed that 36.1% currently prescribed opioids for acute pain, 25.8% for cancer pain, and 40.6% for chronic noncancer pain.

• An average of 97.2% of professionals reported being very confident/somewhat confident that they are currently not at risk of harming patients in prescribing or administering opioids.

• More than a quarter (26.2%) of all respondents indicated that 12.0% expected it that they do not routinely use any risk assessment tools.

• Of the following follow-up management and risk assessment tools, do you use OMT remotely? [Please select only one answer]:

The OMT remotely is likely to be the MOST wanted (select only 1 R or answer)

• Are you currently prescribing opioids for: [Please select only one answer]:

Conclusion

• The REMS is likely to have the MOST impact on: (select only ONE answer)

References


MediCom Worldwide, Inc., Morrisville, PA

On June 23, 2011, MediCom Worldwide, Inc. sent an email invitation to almost 30,000 Emerging Solutions in Pain members (emailed address was verified), inviting them to participate in an 18-question online survey about issues related to safe prescribing and knowledge of the FDA Risk Evaluation and Mitigation Strategies (REMS) for all extended-release and long-acting opioid products. These clinicians were also asked to respond to questions about their current opioid prescribing as well as on various components of the REMS.

• Of the 2,870 members who received the invitation, 702 opened the email invitation, 572 clicked the link to open the survey, and 638 completed the survey.

• The survey was developed with question logic skip logic to one or more answer choices, so not all participants needed to respond to all questions.

• The average time for completion was approximately 6 minutes.

• The survey results were not maintained on an individual basis; instead all survey participants' data were collected and analyzed in aggregate.

• The 2,870 invited participants represented an estimated 2.0% of the addressable audience.

• Thirty-five percent had not yet heard of or read about the FDA REMS elements, while 72% said that there is currently not enough information available to health care professionals about REMS. [2]

• Will the opioid REMS program become an emerging solution in pain? Will it improve the undertreatment of pain and reduce the rates of misuse?

• Prescribing practices showed that 36.1% currently prescribed opioids for acute pain, 25.8% for cancer pain, and 40.6% for chronic noncancer pain.

• An average of 97.2% of professionals reported being very confident/somewhat confident that they are currently not at risk of harming patients in prescribing or administering opioids.

• More than a quarter (26.2%) of all respondents indicated that 12.0% expected it that they do not routinely use any risk assessment tools.

• Of the following follow-up management and risk assessment tools, do you use OMT remotely? [Please select only one answer]:

The OMT remotely is likely to be the MOST wanted (select only ONE answer)

• Are you currently prescribing opioids for: [Please select only one answer]: